A letter from our founder
Trust should be something you can verify.
At Panda Peptides, I want the quality conversation to be simple enough to understand and specific enough to check.
Too many sellers ask you to trust a polished certificate image, a vague “99%+” badge, or a low price. None of those tells you enough on its own. I started Panda because I believed we could source research materials carefully, publish the evidence we actually have, and keep pricing fair.
Our process is still growing, but it is built to be visible. We vet suppliers, buy in defined batches, use independent analytical testing, publish batch documentation, and explain the limits of that documentation.
The point is not to claim perfection. It is to give you a trail you can follow.
It starts with the supplier
We hear from manufacturers and intermediaries constantly. Most do not move beyond the first conversation. Before we buy, we look at communication, consistency, documentation, pricing, and whether the supplier has earned enough confidence to justify a test order.
No supplier gets a permanent pass. A source can perform well for months and still miss on a product or batch. Independent testing is there because supplier trust alone is not a quality system.
We buy and release by batch
We buy around defined batches rather than a stream of one-off vials. That gives us a clear unit to test, release, document, and trace.
Third-party testing is expensive. Batch purchasing lets us pay for meaningful verification without turning every vial into a luxury item. It also gives our fulfillment team a cleaner chain from received material to released inventory.
The testing is independent
Many of our current reports were produced by Janoshik Analytical, an independent third-party analytical laboratory. Where direct verification is available, we link to the report hosted outside Panda’s website as well as showing the COA on our own site.
That matters because certificate images can be copied or edited. A direct lab-hosted record gives you another way to check the compound name, batch identifier, and reported result.
We say what the report proves
Most current Panda reports focus on HPLC purity and identity or composition confirmation, as shown on the report itself. Those results are useful, but they do not automatically prove sterility, endotoxin level, heavy-metal content, residual solvents, or every other quality marker.
We only claim those additional tests when they are documented for the relevant product or batch.
I would rather publish a narrower claim we can support than borrow certainty from a test we did not run.
One batch can include more than one vial size
When multiple vial sizes are filled from the same underlying batch material, we may test a representative sample rather than every vial size individually. The report documents the tested sample and the batch evidence behind the release; it is not a separate finished-vial test for every size.
We are working toward broader batch coverage and clearer size-specific documentation as inventory turns. Until then, the page should make the distinction easy to understand.
Custody matters after testing, too
After release, inventory is stored under controlled conditions appropriate for the material, with attention to heat, light, and handling.
Once a research product leaves controlled custody, we do not place it back into sellable inventory. That can be inconvenient, but it protects the chain of custody for the next customer.
Panda exists because I did not believe the market had to choose between credible documentation and reasonable pricing. Some companies do careful work and charge far more than I think is justified. Others compete on price and ask the buyer to accept too much on faith.
We are building a different kind of company: careful about sourcing, honest about what the evidence shows, fair on price, and willing to improve in public. We will not get every part of that perfect on day one. We will show our work.
That is the standard I want Panda held to.